Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Thyroid Neoplasms 9Hypothyroidism 7Thyroid Diseases 1Thyroid Cancer, Papillary 1Sarcoma, Alveolar Soft Part 1Recurrence 1Postoperative Complications 1Polycystic Ovary Syndrome 1Neoplasms 1Laryngeal Neoplasms 1Infertility, Female 1Head and Neck Neoplasms 1Goiter 1Fatigue 1Depression 1Brain Neoplasms 1Anxiety Disorders 1Advanced Differentiated Thyroid Gland Carcinoma 1

Interventions

Doxorubicin 6Ifosfamide 5Radiotherapy 4pazopanib 3cediranib 3atezolizumab 3Sunitinib 3selinexor 2perifosine 2pembrolizumab 2Trabectedin 2Specimen Handling 2Loperamide 2Gemcitabine 2Filgrastim 2Dacarbazine 2Cisplatin 2Biopsy 2Bevacizumab 2trifluridine tipiracil drug combination 1spartalizumab 1sargramostim 1romidepsin 1lentiviral minigene vaccine of COVID-19 coronavirus 1ixazomib 1indolepropanol phosphate 1futibatinib 1fludarabine 1cabozantinib 1brostallicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Alveolar Soft Part × Thyroxine × Clear all
NCT01391962 2026-02-02

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
34 enrolled 22 charts
Sarcoma

Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon âš¡